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ABSTRACT 
 
Chronic obstructive pulmonary disease (COPD) is one of most common diseases that effect many people around the 
world. Serum magnesium is an independent predictor of frequent readmission due to acute exacerbations of COPD. 
The objective of this study is to look for correlation of serum magnesium levels during acute exacerbation of COPD 
and stable cases of COPD.50 male patients of COPD were selected for measuring serum magnesium levels 
presented with acute exacerbation at the time admission and discharge and results were compared. Serum 
magnesium levels at the time of admission were 1.55(mean) and at the time discharge was 2.32(mean). In our study 
the Z value is 12.6 with reference to Z table, the probability of occurrence (p-value) is less than 0.05 which is 
statistically significant. Hence prevalence of low magnesium levels in acute exacerbation of COPD is high which 
may predict an exacerbation     
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Introduction 
 
Chronic obstructive pulmonary disease (COPD) is one 
of the most common diseases that affect many people 
around the world. COPD is now the fourth leading 
cause of death and is the only disease state that is rising 
in morbidity and mortality amongst the top five killers. 
A recent study conducted to determine the global 
burden of COPD using recent diagnostic criteria [1] 
estimated that the prevalence of moderate to severe 
COPD is 10.1%. Acute exacerbations of COPD are 
common in patients with moderate to severe disease. 
These patients experience 2 exacerbations per year on 
average, with a median recovery time of 7 days. 
Exacerbations of COPD lead to substantial economic 
losses in terms of medical costs, loss of productivity at 
work, and can have a negative impact on patients’ daily 
life and health-related well-being. [8]Since magnesium 
is involved in muscle tone, therefore a decrease in 
magnesium in level in COPD patients represents 
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a factor which is detrimental to respiratory function as 
low magnesium level induces muscle fatigue. A 
growing body of evidence suggests that Mg+2 
deficiency contributes to exacerbations of asthma and, 
as a corollary, that Mg+2 is useful in alleviating 
bronchospasm in these patients [1-3] Sajjad Rajab et al 
studied – relationship between serum magnesium 
levels and acute exacerbation of COPD. They 
concluded that there is increased prevalence of 
hypomagnesaemia in acute exacerbation of COPD and 
is associated with prolonged hospital stay [5] Corradi 
M et al studied – metallic elements in exhaled breath 
condensate and serum of patients with acute 
exacerbation of COPD. Exhaled magnesium and 
manganese levels were influenced by exacerbation of 
COPD, an increase in their concentration respectively 
by 50% & 20% being observed at exacerbation in 
comparison with values obtained at recovery[6] 
Nagomi-Obradovic L et al studied – Evaluation of 
magnesium in serum and urine in patients with 
pulmonary diseases. In patients with acute exacerbation 
of COPD there was a proportional ratio between 
hypomagnesaemia and increased concentration of 
magnesium in 24hr urine probably due to renal loss. 
They concluded that the serious complications of 
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magnesium metabolism derangements & the presence 
of altered cell magnesium content should be taken into 
account in pulmonary ICU patients [7].Even though the 
relationship between serum Mg+2 levels and outcome 
with regard to disease flares in COPD patients has been 
earlier explored, our study is intended to evaluate the 
possible correlation between serum Mg+2 levels in 
COPD patients at the time of exacerbation and after its 
control. 
 
Aim of the study 
 
 To study the correlation between the levels of serum 
magnesium in acute exacerbation of COPD and stable 
cases of COPD. 
 
Materials and methods 
 
 This cross sectional study was conducted on 50 male 
patients who were known cases of COPD, presenting 
with acute exacerbation from December 2010 to March 
2012 in Government Chest Diseases and Tuberculosis 
Hospital, Hanamkonda, A.P, as defined by 
Anthonisens criteria [8-15]. COPD patients who have 
been diagnosed earlier  clinically and by spirometry 
and who had presented with  acute exacerbation  
defined as a change in a patient’s baseline dyspnoea, 
cough and/or sputum beyond day-to-day variability, 
and sufficient to warrant a change in therapy are 
included in the study. Patients with Bronchial asthma, 
other co morbid conditions like Hypertension, Diabetes 
Mallitus, HIV, Pulmonary Tuberculosis, and other 
conditions causing hypomagnesaemia like alcoholism, 
renal causes(ATN),chronic diarrhea, vomiting, crohns 
disease, ulcerative colitis, whipples disease and 
Drugs(loop diuretics,thiazides,gentamycin ,cisplatin) 
were excluded from the study. On the day of study and 
at the time of discharge when patient’s symptoms have 
come near to baseline, their symptoms – Cough, 
Sputum, Dyspnoea were analysed and scored. [16-
21]Severity of dyspnea is scored by Modified MMRC 
scale.5ml of venous blood sample was collected in a 
vaccutainer and sent to the laboratory on the day of 
admission and discharge (i.e, when the patient 
symptoms returned to their baseline levels).Serum 
magnesium levels were analyzed from 1 ml of the fresh 
supernatant unhemolyzed serum of the centrifuged 
sample and the results were recorded.[22-29] In our 
study serum magnesium was analyzed by calorimetric 
method using metallochromic dye calmagite. This is a 
rapid, easy and accurate method of determination of 
magnesium in serum [30,31].We used VITROS 5600 
analyzer with automated procedure. Instrument is 
calibrated using an aqueous Magnesium Standard 
(2.4mg/dl). The integrity of the reaction was monitored 
by normal and abnormal control sera with known 
magnesium concentrations. Our lab normal range for 
serum magnesium is 1.8-2.4 mg/dl. 
      
Fig 1: VITROS 5600 Analyzer 
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Statistical analysis and descriptive values 
This cross-sectional study was conducted on 50 patients. All the patients were males and all were smokers. 
Table 1: Master chart showing patients and statistical analysis 
S No. Patient ID Number Age Sex Se. Mg at the time of 
admission mg/dl 
Se. Mg at the time of 
discharge mg/dl 
1 01 60yrs M 1.4 2 
2 02 68yrs M 1.5 2.3 
3 03 62yrs M 1.5 2.2 
4 04 60yrs M 1.7 2,4 
5 05 65yrs M 2.3 2.4 
6 06 62yrs M 1.9 2.4 
7 07 70yrs M 1.3 2 
8 08 65yrs M 2 2.2 
9 09 55yrs M 2.2 2.3 
10 10 58yrs M 2.3 2.4 
11 11 70yrs M 2 2.2 
12 12 65yrs M 1.9 2 
13 13 65yrs M 1.4 2.2 
14 14 70yrs M 1.5 2.4 
15 15 55yrs M 1.6 2.3 
16 16 65yrs M 1.4 2.3 
17 17 60yrs M 1.3 2.2 
18 18 70yrs M 1.3 2.3 
19 19 60yrs M 1.4 2.3 
20 20 65yrs M 1.5 2.2 
21 21 60yrs M 1.4 2.1 
22 22 55yrs M 1.3 2 
23 23 62yrs M 1.6 2.3 
24 24 60yrs M 1.3 1.9 
25 25 67yrs M 1.4 1.8 
26 26 70yrs M 1.6 2.4 
27 27 60yrs M 1.7 2.3 
28 28 59yrs M 1.5 2.2 
29 29 70yrs M 1.3 2.3 
30 30 55yrs M 1.4 1.9 
31 31 65yrs M 1.5 2.3 
32 32 60yrs M 1.6 2.4 
33 33 70yrs M 1.1 2.2 
34 34 60yrs M 1.3 2.4 
35 35 56yrs M 1.3 2.4 
36 36 66yrs M 1.5 2.3 
37 37 68yrs M 1.2 1.9 
38 38 70yrs M 1.3 2 
39 39 60yrs M 1.4 2.2 
40 40 65yrs M 1.3 2.4 
41 41 63yrs M 1.5 2.4 
42 42 65yrs M 1.4 2.3 
43 43 62yrs M 1.5 2.4 
44 44 70yrs M 1.3 2.2 
45 45 65yrs M 1.4 2 
46 46 55yrs M 1.6 2.4 
47 47 60yrs M 1.4 2.3 
48 48 58yrs M 1.9 2.3 
49 49 67yrs M 2 2.2 
50 50 55yrs M 2.1 2.4 
 Mean 62.96  1.55 2.232 
 SD 4.89452964  0.288 0.255 
 
 
Asian Pac. J. Health Sci., 2016; 3(1):56-64                                          e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Murthy et al                            ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016; 3(1):56-64 
www.apjhs.com      59 
 
Age composition 
 
The age group of the study group ranged from 55 – 70 yrs. The mean age was 62.96 ± 4.8 yrs. 
Table 2: Age group and number of patients 
                     Age group                  No of patients 
                     55 – 60                     21 
                     61 – 70                     29 
                     Total                     50 
 
 
 
Fig 2: Age group and number of patients 
 
Symptoms Score 
 
On the day of study, three symptoms – cough with increased sputum volume, increased sputum purulence and 
dyspnoea were analysed and cumulative score was taken as 1 – 3 grades. 
 
Table 3: Symptom score and number of patients 
Symptom score No of patients 
1 11 
2 19 
3 20 
 
 
 
Fig 3: Symptom score and number of patients 
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Symptom score 
 
At the time of admission, out of 50 patients studied 11 (22%) had symptom score 1; 19 (38%) had symptom score 2 
and 20 (40%) had symptom score 3. All 50 patients had dyspnoea; 39 patients had cough with increased sputum 
volume and 20 patients had cough with increased sputum volume & increased sputum purulence.The mean 
symptom score was  : 2.18,SD :± 0.89 
 
MMRC dyspnoea scale grading 
 
Patients were graded according to MMRC dyspnoea scale as grades 0 to 4. 
Table 4: MMRC dyspnoea scale grading 
           MMRC dyspnea scale                    No of patients 
                              0                                0 
                              1                                5 
                              2                                8 
                              3                                25 
                              4                                12 
 
 
Fig 4: MMRC dyspnoea scale 
 
MMRC dyspnoea scale 
 
Out of 50 patients studied 5 patients had grade I 
dyspnoea; 8 patients had grade II dyspnoea; 25 patients 
had grade III dyspnoea and 12 patients had grade IV 
dyspnoea. The mean MMRC dyspnoea grade was: 
2.88,SD:  ±0.81 
At the time of discharge 45 (90 %) patients had grade- 
I dyspnoea; 5 (10 %)   patients had grade-II dyspnoea. 
The initial increased sputum volume and purulence in 
patients was reduced at the time of discharge. 
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Serum magnesium levels at the time of admission 
 
Table 5: Serum magnesium level and number of patients 
 
Serum magnesium level (mg/dl) No of patients 
1.8 – 2.4 10 
1.5 – 1.7 16 
1 – 1.4 24 
 
 
Fig 5: Serum magnesium level and number of patients 
                   
 
Serum magnesium levels 
 
The mean serum magnesium level was:  1.576,SD:  ± 0.336 
 
Serum magnesium levels at the time of discharge 
 
Table 6: Serum magnesium levels at the time of discharge 
     Serum magnesium level (mg/dl)                     No of patients 
                     1.8 – 2                         10 
                     2.1 – 2.4                          40 
 
 
  
Fig 6: Serum magnesium levels at the time of discharge 
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 Serum magnesium levels 
 
The mean serum magnesium level was: 1.91,SD:± 0.364 
 
Average values for the parameters studied 
 
Table 7: Average values for the parameters studied 
 
Parameter studied  Values 
Dyspnea (MMRC)  Mean:2.88,SD: ±0.81 
Symptom score Mean: 2.18,SD: ±0.89 
Serum magnesium levels at the time of admission   Mean : 1.55,SD : ±0.288 
Serum magnesium levels at the time of discharge   Mean : 2.232,SD : ± 0.255 
 
Correlation between serum magnesium and acute exacerbation of COPD: 
Z  = X̅1 - X̅2 / √ ̅S̅D̅12/n1 +SD22/n2 
( X̅1 : 1.55; X̅2 : 2.32;  SD1 : 0.28; SD2 : 0.25; n1 : 50; n2 : 50 ) 
Z =  1.55 – 2.32 / √0̅.0̅̅0̅16̅̅5̅ ̅+̅ 0̅̅.̅0̅0̅13̅ ̅
Z  = - 0.682 / 0.054 
Z  =  - 12.6 
 
n1: number of patients in 1st group; SD1: standard deviation of group 1; X̅1: mean ofmagnesium levels of group 1; n2: 
number of patients in 2nd group; X̅2: mean of magnesium levels of group 2 ; SD2 : standard deviation of group 2 ; 
In our study Z value is 12.6, with reference to the‘z’ table,the probability of occurrence(p value) is less than 
0.05.Hence the serum magnesium level is statistically significant.  
 
Discussion 
Much of the impact of COPD is due to the 
constellation of symptoms that is commonly termed an 
exacerbation. Major emphasis in the management of 
patients with COPD must be on the maintenance of 
stability. Bach et al [34] noted that antibiotics, 
bronchodilators, corticosteroids, and non-invasive 
positive-pressure ventilation remain the mainstay of 
therapy, but they pointed out the need for the 
identification of risk factors and the limited utility of 
diagnostic predictors of the course of COPD. There is a 
growing awareness on the role of magnesium in 
pulmonary disease. The significance of Mg+2 as both a 
risk factor and potential therapeutic agent in patients 
with COPD comes from the relatively well-established 
role of Mg+2 in the treatment of acute asthma. There 
are few studies which have shown the role of serum 
magnesium in COPD patients as a risk factor for acute 
exacerbation and for frequent hospitalization. Our 
study was a cross-sectional study , where we studied 
serum magnesium levels at the time of admission and 
at the time of discharge and both the values were 
compared. The relationship between serum magnesium 
and acute exacerbation of COPD was studied earlier by 
Aziz et al; Bhatt, S.P. et al; Sajjadrajab et al;Aziz et 
al., examined serum Mg+2 levels in an unselected group 
of COPD patients with clear symptoms of exacerbation 
and compared these to a group of patients reporting for 
routine clinic visits and in no apparent distress from the 
sequelae of bronchospasm, generally considered to 
indicate an exacerbation. Mean serum magnesium 
levels at the time of AECOPD was 0.77± 0.10 mmol/L. 
Mean serum magnesium levels in stable COPD patients 
was 0.91±0.10 mmol/L. Patients  with acute 
exacerbation of COPD had significantly lower 
concentrations of serum magnesium and they suggest 
that low levels of serum magnesium may serve as a 
risk factor for acute exacerbation of COPD. Sajjadrajab 
et al studied serum magnesium levels in a group of 77 
patients who presented with acute exacerbation of 
COPD. Serum magnesium levels were determined at 
the time of exacerbation, at discharge and one month 
after discharge. They reported that  the mean serum 
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magnesium levels of patients with acute exacerbation 
of COPD was statistically significantly lower 
1.88±0.67 mg/dl (mean±SD) than serum magnesium of 
stable COPD patients 2.30±0.36 (mean±SD). They 
observed the association of hypomagnesaemia with 
acute exacerbation of COPD. Bhatt S.P.et al., in their 
series of 100 patients admitted with a diagnosis of 
acute exacerbation of COPD was retrospectively 
followed from the time of index admission until next 
admission. The sole predictor of frequent readmissions 
was serum magnesium level (1.77+/-0.19 vs. 1.86+/-
0.24mEq/L; adjusted odds ratio 0.003, 95% Confidence 
intervals <0.001-0.55; p=0.03). [32, 33] They observed 
that serum magnesium is an independent predictor of 
frequent readmissions due to acute exacerbation of 
COPD and is an easily modifiable risk factor. 
David Holmes et al.,in their study observed that COPD 
patients with low serum magnesium levels are at 
increased risk for hospital admission for acute 
exacerbation compared to patients with normal serum 
magnesium levels. 
 
Conclusion 
 
The prevalence of hypomagnesaemia in acute 
exacerbation of COPD is high. 
Low serum magnesium may predict acute exacerbation 
of COPD. 
Low serum magnesium levels may be a risk factor for 
acute exacerbation of COPD for which further large 
scale studies are required. 
Low serum magnesium is a modifiable risk factor. 
Limitations: sample size was less & females were not 
included in the study. 
Further large scale studies are required to determine the 
role of magnesium in the treatment of acute 
exacerbation of COPD. 
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